Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists
AssigneePolfarmex S.A.
InventorsPiotr Kopczacki, Mieczyslaw Wosko, Jaroslaw Walczak, Krzysztof Walczynski
Life of this patent
Estimating the term…
Loading patent…
AssigneePolfarmex S.A.
InventorsPiotr Kopczacki, Mieczyslaw Wosko, Jaroslaw Walczak, Krzysztof Walczynski
Estimating the term…
The present invention relates to compounds of formula (I), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where R1 and R2 are, independently, hydrogen, halogen, C1_3 alkyl or C1-3alkoxy; R3 is phenyl optionally substituted by R4 and R5 which are, independently hydrogen, halogen, C1-3 alkyl, C1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, N,N-diC1-3alkyl-amide, carboC1-3 alkoxy or C1-3alkylsulphone groups; R3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.
A compound, including enantiomers, stereoisomers, cis-, trans-isomers and their racemic mixture and mixture of geometric isomers, or pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in formula (I)
The compound of claim (1) where R1 and R2 are C1-3alkyl groups, and R3=phenyl, and the optional substituents in R4 and R5 are hydrogen, fluorine, chlorine or bromine.
The compound of claim (1) where R1 and R2 are C1-3alkoxy groups and R3=phenyl, and the optional substituents in R4 and R5 are hydrogen, fluorine, chlorine or bromine.
The compound of claim (1) where R1 and R2 are fluorine, chlorine or bromine groups and R3=phenyl, and the optional substituents in R4 and R5 are hydrogen, fluorine, chlorine or bromine.
The compound of claim (1) where R1 and R2 are hydrogen and R3=phenyl, and the optional substituents in R4 are hydrogen or methyl or chlorine and R5 are hydrogen or methyl or fluorine or chlorine or methyl group or methoxy group or nitrile group.
The compound of claim (1) where R1 and R2 are hydrogen, fluorine, chlorine or bromine and R3 unsubstituted pyridynyl, the pyridynyl moiety contains nitrogen at 3-position in benzene ring.
A pharmaceutical composition having histamine H1-antagonists activity comprising a histamine blocking effective amount of a compound according to claim (1) and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.